- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Arecor Therapeutics - Notice of Results | - | RNS | ||
| 11.09. | Arecor Therapeutics - Arecor presents positive AT278 data at EASD | - | RNS | ||
| 03.09. | Arecor Therapeutics - Arecor announces AT278 presentation at EASD 2024 | - | RNS | ||
| 08.08. | Arecor Therapeutics - Result of General Meeting and Total Voting Rights | 2 | RNS | ||
| 23.07. | Arecor Therapeutics - Posting of Circular and General Meeting | - | RNS | ||
| 23.07. | Arecor Therapeutics - Result of WRAP Retail Offer | - | RNS | ||
| 19.07. | Arecor Therapeutics - Result of Placing and Subscription | 1 | RNS | ||
| 19.07. | Arecor Therapeutics - WRAP Retail Offer to raise up to £1 million | - | RNS | ||
| 19.07. | Arecor Therapeutics - Proposed Placing and Subscription | 1 | RNS | ||
| 28.06. | Arecor Therapeutics - Result of AGM | - | RNS | ||
| 10.06. | AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs | 1 | Alliance News | ||
| 10.06. | UK's Arecor Therapeutics slumps on rising working capital needs | 2 | Reuters | ||
| 10.06. | Arecor Therapeutics shares dive as says needs funding in third quarter | 2 | Alliance News | ||
| 10.06. | Arecor Therapeutics shares tank on funding update | 1 | Sharecast | ||
| 10.06. | Arecor Therapeutics - Trading and Funding Update | 1 | RNS | ||
| 31.05. | Arecor Therapeutics - Posting of 2023 Annual Report and Notice of AGM | 1 | RNS | ||
| 23.05. | Arecor Therapeutics - Grant of Options and PDMR Dealing | - | RNS | ||
| 21.05. | Arecor Therapeutics - Arecor to host company and KOL webinar today | - | RNS | ||
| 20.05. | Arecor Therapeutics plc: At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes | 88 | GlobeNewswire (Europe) | Arecor Therapeutics plc("Arecor" or "the Company") AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2... ► Artikel lesen | |
| 20.05. | Arecor Therapeutics hails positive profile for insulin AT278 | 2 | Alliance News |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,090 | -2,30 % | Biotech Report: Biontech gesucht, Qiagen behauptet | (shareribs.com) Frankfurt / New York 16.09.2024 - Biotech-Aktien zeigten sich zum Wochenauftakt im deutschen Handel uneinheitlich. Für Biotest und Evotec ging es abwärts. Qiagen konnten sich behaupten.... ► Artikel lesen | |
| ELIEM THERAPEUTICS | 8,430 | +1,81 % | Eliem Therapeutics, Inc.: Eliem Therapeutics Reports Second Quarter Financial Results | Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred... ► Artikel lesen | |
| ARVINAS | 25,630 | +0,12 % | Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen | |
| EVOTEC | 6,005 | -5,36 % | Das ist doch nicht zu glauben! 250 % mit Ansage: Bayer, Vidac Pharma, Evotec und Valneva | Die Börse haussiert von Woche zu Woche, doch der BioTech-Sektor bleibt hartnäckig auf der Strecke. Mit der ersten Zinssenkung in Europa ist jedoch der Pfad der niedrigeren Finanzierungsmöglichkeiten... ► Artikel lesen | |
| ARCELLX | 86,65 | +1,42 % | ACLX, HROW Deliver Triple-Digit Returns - Did You Cash In? | WASHINGTON (dpa-AFX) - Many traders seek instant gratification in the stock market. Some stocks offer quick profits, while others require a patient, long-term approach for significant returns.... ► Artikel lesen | |
| DYNE THERAPEUTICS | 36,580 | +0,47 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,350 | +5,14 % | ROUNDUP/Aktien New York: Neue Rekorde vor US-Zinsentscheid | NEW YORK (dpa-AFX) - Vor dem Zinsentscheid der US-Notenbank Fed bleiben die Anleger an den New Yorker Börsen optimistisch. Der Leitindex Dow Jones Industrial markierte am Dienstag gleich zu Beginn... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,670 | -1,42 % | Jones Trading stuft Beam Therapeutics auf "Halten" ein | ||
| SPRINGWORKS THERAPEUTICS | 34,410 | -2,66 % | SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | - PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,950 | +1,06 % | EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 58,66 | +10,78 % | Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer | SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,780 | +1,88 % | Vera Therapeutics director sells over $696k in company stock | ||
| RECURSION PHARMACEUTICALS | 6,810 | -1,87 % | Angle PLC Announces Agreement with Recursion Pharmaceuticals | New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating... ► Artikel lesen | |
| IMMUNOVANT | 29,240 | -1,18 % | Immunovant Inc.: Immunovant Provides Update on Graves' Disease Development Program | High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on... ► Artikel lesen | |
| NURIX THERAPEUTICS | 25,630 | +2,27 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment... ► Artikel lesen |
Das Unternehmen ARECOR THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,015 (+1,88 %) liegt der Kurs bei 0,815 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARECOR THERAPEUTICS PLC finden Sie auf Wallstreet Online.
